Effect of continued pirfenidone treatment following a ≥ 15% decline in 6-minute walk distance (6MWD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis from 3 pivotal studies
Steven Nathan, Carlo Albera, Ulrich Costabel, Ian Glaspole, Marilyn Glassberg, Lisa Lancaster, David Lederer, Carlos Pereira, Jeffrey Swigris, Andrey Pavlov, John Stauffer, Bann-Mo Day, Willis Chou, Athol Wells
European Respiratory Journal 2016 48: OA1765; DOI: 10.1183/13993003.congress-2016.OA1765
Steven Nathan
1Advanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VAUnited States
Carlo Albera
2Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
Ulrich Costabel
3Department of Pneumology, Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany
Ian Glaspole
4Department of Immunology, Alfred Hospital, Melbourne, Australia
Marilyn Glassberg
5Department of Pulmonology, University of Miami Miller School of Medicine, Miami, FLUnited States
Lisa Lancaster
6Department of Medicine, Vanderbilt University Medical Center, Nashville, TNUnited States
David Lederer
7Department of Clinical Medicine, Columbia University Medical Center, New York, NYUnited States
Carlos Pereira
8Department of Medicine, Paulista School of Medicine, Federal University of São Paulo, São Paulo, Brazil
Jeffrey Swigris
9Department of Medicine, National Jewish Health, Denver, COUnited States
Andrey Pavlov
10Biostatistics, Everest Clinical Research, Markham, ONCanada
John Stauffer
11US Medical Affairs, Genentech, Inc., South San Francisco, CAUnited States
Bann-Mo Day
11US Medical Affairs, Genentech, Inc., South San Francisco, CAUnited States
Willis Chou
11US Medical Affairs, Genentech, Inc., South San Francisco, CAUnited States
Athol Wells
12Department of Respiratory Medicine, Royal Brompton Hospital, London, United Kingdom
Vol 48 Issue suppl 60
Table of Contents
Effect of continued pirfenidone treatment following a ≥ 15% decline in 6-minute walk distance (6MWD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis from 3 pivotal studies
Steven Nathan, Carlo Albera, Ulrich Costabel, Ian Glaspole, Marilyn Glassberg, Lisa Lancaster, David Lederer, Carlos Pereira, Jeffrey Swigris, Andrey Pavlov, John Stauffer, Bann-Mo Day, Willis Chou, Athol Wells
European Respiratory Journal Sep 2016, 48 (suppl 60) OA1765; DOI: 10.1183/13993003.congress-2016.OA1765
Effect of continued pirfenidone treatment following a ≥ 15% decline in 6-minute walk distance (6MWD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis from 3 pivotal studies
Steven Nathan, Carlo Albera, Ulrich Costabel, Ian Glaspole, Marilyn Glassberg, Lisa Lancaster, David Lederer, Carlos Pereira, Jeffrey Swigris, Andrey Pavlov, John Stauffer, Bann-Mo Day, Willis Chou, Athol Wells
European Respiratory Journal Sep 2016, 48 (suppl 60) OA1765; DOI: 10.1183/13993003.congress-2016.OA1765